The ubiquitin-proteasome pathway is a new partner for the control of insulin signaling.
Insulin signaling is a transitory effect that has to be tightly controlled in magnitude and duration in order to maintain cell homeostasis. Recent reports have demonstrated that members of the ubiquitin-proteasome pathway represent new partners that have to be taken into account for the regulation of insulin action. The protein amounts of the different signaling molecules involved in insulin action are regulated by their rates of synthesis and degradation. The ubiquitin-proteasome system is involved in the internalization of the insulin receptor, in the control of the amount of insulin receptor substrates 1 and 2, and in insulin degradation. Finally, ubiquitination and sumoylation regulate transcription factors and nuclear receptors that mediate insulin-induced gene expression. It is well known from transgenic models that inappropriate levels of signaling molecules strongly affect insulin action. In humans also, several reports have provided evidence of altered levels of key proteins involved in insulin action in pathologies such as type 2 diabetes. The relationship between these abnormalities and the ubiquitin-proteasome pathway has yet to be clarified, but clarifying the role of ubiquitination in insulin action will certainly lead to a better understanding of insulin resistance.